Slashdot videos: Now with more Slashdot!
We've improved Slashdot's video section; now you can view our video interviews, product close-ups and site visits with all the usual Slashdot options to comment, share, etc. No more walled garden! It's a work in progress -- we hope you'll check it out (Learn more about the recent updates).
Head transplants has been tried before. In 1970, Robert White led a team at Case Western Reserve University in Cleveland, US, that tried to transplant the head of one monkey on to the body of another. The surgeons stopped short of a full spinal cord transfer, so the monkey could not move its body. Despite Canavero's enthusiasm, many surgeons and neuroscientists believe massive technical hurdles push full body transplants into the distant future. The starkest problem is that no one knows how to reconnect spinal nerves and make them work again. "This is such an overwhelming project, the possibility of it happening is very unlikely," says Harry Goldsmith."
Emanuel says that we need to use prize money as an incentive. "What if the United States government — maybe in cooperation with the European Union and Japan — offered a $2 billion prize to the first five companies or academic centers that develop and get regulatory approval for a new class of antibiotics?" Because it costs at least $1 billion to develop a new drug, the prize money could provide a 100 percent return — even before sales. "From the government perspective, such a prize would be highly efficient: no payment for research that fizzles. Researchers win only with an approved product. Even if they generated just one new antibiotic class per year, the $2-billion-per-year payment would be a reasonable investment for a problem that costs the health care system $20 billion per year." Unless payers and governments are willing to provide favorable pricing for such a drug, the big companies are going to focus their R&D investments in areas like cancer, depression, and heart disease where the return-on-investments are much higher.